Almost two decades ago, there were limited options for ulcerative colitis treatment. Choosing the right ulcerative colitis drugs depends on the severity of the condition and the patient's response to previous therapies. To manage patients effectively, physicians often prescribe a combination of ulcerative colitis medications. The readily available ulcerative colitis therapies were aminosalicylates and immunomodulators (azathioprine, 6-mercaptopurine, and methotrexate), with biologics (Adalimumab, Golimumab, Infliximab, Ustekinumab, and Vedolizumab) reserved for patients with more refractory or severe disease. However, today we have several approved classes of ulcerati...
